Effects of adjuvant danhong injection therapy on nerve injury and platelet activation markers in patients with acute cerebral infarction

Objective:To investigate the effects of adjuvant danhong injection therapy on nerve injury and platelet activation markers in patients with acute cerebral infarction.Methods: A total of 102 patients with acute cerebral infarction who were treated in our hospital between January 2016 and September 2017 were reviewed and divided into the routine group (n=54) who received conventional therapy and the danhong injection group who received adjuvant danhong injection therapy. The differences in the contents of nerve injury indexes in serum and platelet activation markers in peripheral blood were compared between the two groups before treatment, after 3 d of treatment and after 7 d of treatment.Results: There was no statistically significant difference in the contents of nerve injury indexes in serum and platelet activation markers in peripheral blood between the two groups before treatment. After 3 d of treatment and after 7 d of treatment, copeptin, H-FABP and NSE contents in serum of danhong injection group were lower than those of routine group whereas BDNF and bFGF contents were higher than those of routine group;CD62p, CD42b, PAC-1 and PMA contents in peripheral blood were lower than those of routine group.Conclusion: Conventional therapy combined with adjuvant danhong injection therapy can effectively reduce the degree of nerve injury and inhibit the platelet activation in patients with acute cerebral infarction.

Effects of Yinxingdamo Injection Combined with Oxiracetam Capsule on Cognitive Function and Neurological Deficit in Patients with Acute Cerebral Infarction

OBJETTIVE: To observe the effects of Yinxingdamo Injection combined with oxiracetam capsule on cognitive function and neurological deficit in patients with acute cerebral infarction. METHODS: A total of 76 patients with acute cerebral infarction were randomly divided into observation group and control group, with 38 patients in each group. Patients in the control group were treated with conventional western medicine and oxiracetam capsules while patients in the observation group were given Yinxingdamo injection intravenous drip treatment on the basis of the same treatment. After 4 weeks of treatment, the cognitive function of the two groups before and after treatment was observed [Simple Intelligence Scale(MMSE Score), Montreal Cognitive Assessment Scale(MoCA Score)], Neurological Deficit [Chinese Stroke Scale(CSS Score), Daily Life Activity ability(ADL score)], free radical biochemical indicators [malondialdehyde(MDA), oxide dismutase(SOD)] changes, and statistical effects of two groups. RESULTS: After treatment, the total effective rate of the observation group was 92.1%, which was significantly higher than 73.7% of the control group(P < 0.05). The MMSE score and MoCA score of the two groups were significantly increased after treatment(P < 0.05), and the MMSE score and MoCA score inobservation group were significantly increased after treatment than the control group(P < 0.05). The CSS scores of the two groups were significantly decreased after treatment(P < 0.05), and the ADL scores were significantly increased(P < 0.05). The improvement of CSS score and ADL score in the observation group were significantly better than those in the control group(P < 0.05), and serum MDA levels were significantly decreased in both groups after treatment(P < 0.05), and SOD levels were significantly increased(P < 0.05), and the improvement of MDA and SOD levels in the observation group was significantly better than that in the control group group(P < 0.05). CONCLUSION: Yinxingdamo injection combined with oxiracetam capsule can effectively inhibit the oxygen free radical reaction injury in patients with acute cerebral infarction, and significantly improve the symptoms of cognitive dysfunction and neurological deficit in patients. Its curative effect is exact and worthy of clinical application.

Effect of Danhong injection on neuroethology changes, cell injury and apoptosis in rats with cerebral infarction

Objective:To study the effect of Danhong injection on neuroethology changes, cell injury and apoptosis in rats with cerebral infarction.Methods: SD rats were selected as experimental animals and divided into control group, cerebral infarction group and Danhong group, control group received sham operation, cerebral infarction group were made into cerebral infarction animal models and Danhong group were made into cerebral infarction animal models and then received Danhong injection for intervention. After the intervention, water maze experiment was used to assess the neuroethology changes of rats, and the serum and brain tissue were collected to determine nerve injury molecules and apoptosis molecules.Results: 2 weeks, 4 weeks and 6 weeks after intervention, the escape latency and the course to find platform of cerebral infarction group were higher than those of control group and the number of platform crossing were lower than those of control group;the escape latency and the course to find platform of Danhong group were lower than those of cerebral infarction group, and the number of platform crossing were higher than those of cerebral infarction group;6 weeks after intervention, CK-BB, LDH, NSE and S100β levels in serum as well as ROS, MDA, JNK1, JNK2, c-Jun, ATF-2 and Bax levels in brain tissue of cerebral infarction group were significantly higher than those of control group while GSH-PX, T-SOD and CAT levels in brain tissue were significantly lower than those of control group;CK-BB, LDH, NSE and S100β levels in serum as well as ROS, MDA, JNK1, JNK2, c-Jun, ATF-2 and Bax levels in brain tissue of Danhong group were significantly lower than those of cerebral infarction group while GSH-PX, T-SOD and CAT levels in brain tissue were significantly higher than those of cerebral infarction group. Conclusion:Danhong injection can reduce the neurocyte damage and inhibit the neurocyte apoptosis to improve the neurological function of rats with cerebral infarction.

Effect of danhong injection combined with sodium ozagrel on serum IL-8, TNF-α, VEGF, TBIL and NSE in old patients with acute cerebral infarction

Objective:To study the effect of danhong injection combined with sodium ozagrel on serum IL-8, TNF-α, VEGF, TBIL and NSE in old patients with acute cerebral infarction.Methods:A total of 100 old patients with acute cerebral infarction in our hospital from August 2014 to December 2016 were enrolled in this study. The subjects were divided into the control group (n=50) and the treatment group (n=50) randomly. The control group was treated with sodium ozagrel, the treatment group was treated with danhong injection combined with sodium ozagrel, and both the two groups were treated for 14 days. The serum IL-8, TNF-α, VEGF, TBIL and NSE of the two groups before and after treatment were compared.Results:There were no significantly differences of the serum IL-8, TNF-α, VEGF, TBIL and NSE of the two groups before treatment. The serum IL-8, TNF-α, NSE levels of the two groups after treatment were significantly lower than before treatment, the serum VEGF, TBIL levels of the two groups after treatment were significantly higher than before treatment, and that of the treatment group after treatment were significantly better than the control group.Conclusion:Danhong injection combined with sodium ozagrel can significantly reduce the serum IL-8, TNF-α, NSE levels, improve the serum VEGF, TBIL levels, and reduce inflammation, promote the nerve functional recovery of the old patients with acute cerebral infarction, and it was worthy clinical application.

醒脑静联合丁苯酞治疗急性脑梗死的疗效观察及对血液流变学、外周血IL-23、MIP-1α水平的影响

目的:研究醒脑静注射液联合丁苯酞软胶囊治疗急性脑梗死(ACI)的疗效,以及对血液流变学、外周血白细胞介素-23(IL-23)、巨噬细胞炎性蛋白-1α(MIP-1α)水平的影响。方法:按随机数字表法将2018年7月—2022年7月河南科技大学第一附属医院诊治的ACI患者106例分为2组,各53例。对照组口服丁苯酞软胶囊,观察组采用丁苯酞软胶囊联合醒脑静注射液治疗。比较2组治疗后的临床疗效、治疗前后美国国立卫生研究院卒中量表(NIHSS)评分、血液流变学指标、外周血IL-23和MIP-1α水平等。结果:治疗后,观察组总有效率为94.34%,高于对照组的79.25%(P<0.05);2组NIHSS评分均较干预前明显降低,且观察组低于对照组,差异均有统计学意义(P<0.05);2组血浆黏度(PV)、纤维蛋白原(FIB)、血细胞比容(HCT)均较干预前明显降低,且观察组低于对照组,差异均有统计学意义(P<0.05);2组IL-23、MIP-1α水平均较干预前明显降低,且观察组低于对照组,差异均有统计学意义(P<0.05)。结论:醒脑静注射液联合丁苯酞软胶囊对ACI患者有较好疗效,能明显降低NIHSS评分,调节血液流变学指标,降低外周血IL-23、MIP-1α水平。

醒脑静注射液联合丁苯肽胶囊治疗急性脑梗死临床观察

目的分析醒脑静注射液联合丁苯酞软胶囊治疗对急性脑梗死(ACI)患者神经功能恢复及对外周血白细胞介素-23(IL-23)、巨噬细胞炎性蛋白-1α(MIP-1α)水平的影响。方法选取2021-01—2022-12皖北煤电集团总医院收治的118例ACI患者,随机分为对照组与研究组各59例,对照组给予丁苯酞软胶囊治疗,研究组给予醒脑静注射液联合丁苯酞软胶囊治疗,均治疗10 d,比较2组患者的临床疗效、神经功能[美国国立卫生院脑卒中量表(NIHSS)评分、欧洲卒中量表评分(ESS)]、外周血炎性因子[IL-23、MIP-1α水平]、生活质量[Barthel指数量表(BI)评分]以及不良反应发生情况。结果治疗后研究组患者的总有效率为94.92%高于对照组的79.66%(P<0.05),NIHSS评分[(3.15±0.33)分]低于对照组[(4.70±1.08)分],ESS评分[(61.37±7.53)分]高于对照组[(54.54±6.87)分](P<0.05),外周血IL-23水平[(32.82±4.35)ng/L]及MIP-1α水平[(10.37±2.53)ng/L]均低于对照组[(45.36±5.14)ng/L,(18.54±3.87)ng/L](P<0.05),BI评分[(81.02±5.39)分]高于对照组[(65.83±5.57)分](P<0.05)。研究组患者的不良反应发生率(8.47%)与对照组(13.56%)比较无统计学差异(P>0.05),2组患者均未见有明显严重不良反应发生。结论在丁苯酞软胶囊基础上给予ACI患者醒脑静注射液治疗,可提升疗效,有效促进患者神经功能恢复,改善机体炎性反应,提高生活质量,安全性好。

利拉鲁肽联合通心络胶囊对2型糖尿病合并脑梗死患者的疗效及安全性评价

目的探讨利拉鲁肽注射液联合通心络胶囊对脑梗死合并2型糖尿病患者相关指标的影响,并观察其用药安全性。方法选取150例脑梗死合并2型糖尿病患者,并随机将其分为利拉鲁肽组、通心络组和联合治疗组,每组50例。利拉鲁肽组在给予患者常规治疗的同时注射利拉鲁肽,通心络组在给予患者常规治疗的同时口服通心络胶囊,联合治疗组在给予患者常规治疗的同时注射利拉鲁肽并联合口服通心络胶囊。比较未联合用药的两组(利拉鲁肽组、通心络组)及联合治疗组对脑梗死合并2型糖尿病患者的颈动脉粥样硬化、血脂、炎症相关指标在治疗前后的变化情况。其中,用颈动脉内膜中层厚度(Intima-media thickness,IMT)评价颈部动脉粥样硬化程度;血脂指标包括总胆固醇(TC)、甘油三酯(TG)、低密度脂蛋白(LDL-C)、高密度脂蛋白(HDL-C);炎症指标包括肿瘤坏死因子-α(TNF-α)、白细胞介素-6(IL-6)、高敏C反应蛋白(hs-CRP);观察患者在治疗过程中不良反应发生情况,检测治疗前后血常规及肝功肾功指标,评估用药安全性。结果治疗前,3组患者上述指标比较差异均无统计学意义(P>0.05);治疗后,未联合用药的两组患者其IMT、TC、TG、LDL-C、TNF-α、IL-6、hs-CRP水平与治疗前比较均降低(P<0.05),HDL-C水平与治疗前比较有所上升(P<0.05),联合治疗组的HDL-C水平与未联合用药的两组比较上升显著(P<0.05),其余指标较未联合用药的两组下降明显(P<0.05);3组患者不良反应发生情况比较差异无统计学意义(P>0.05)。结论利拉鲁肽注射液和通心络胶囊可以稳定脑梗死合并2型糖尿病患者颈动脉斑块,调节血脂,控制炎性细胞因子的释放,减少其对神经细胞的损伤,二者联合用药治疗效果较单一用药效果好,且其安全性高。

丹红注射液联合丁苯酞注射液治疗对急性脑梗死神经功能及炎性因子水平的影响

目的 探讨丹红注射液联合丁苯酞注射液治疗对急性脑梗死患者神经功能及炎性因子水平的影响。方法 将100例急性脑梗死患者随机分为两组各50例。对照组采用丁苯酞注射液治疗,观察组在对照组基础上采用丁苯酞注射液治疗,两组均连续治疗14 d。比较两组的神经功能、炎性因子水平及不良反应。结果 治疗后,观察组NIHSS评分及TNF-α、 hs-CRP、 IL-6水平低于对照组(P <0.05)。治疗期间,两组不良反应发生率(10.00%vs. 16.00%)比较无统计学差异(P>0.05)。结论 丹红注射液联合丁苯酞注射液治疗可显著改善急性脑梗死患者神经功能损伤,减轻机体炎性反应,且安全性较高,值得临床推广。

丹红注射液联合丁苯酞注射液治疗急性脑梗死患者的临床效果及对氧化应激的影响

目的 分析丹红注射液联合丁苯酞注射液治疗急性脑梗死患者的临床效果及对氧化应激的影响。方法 将我院2020年12月至2022年12月收治的64例急性脑梗死患者以治疗方案不同分为常规组和观察组,每组32例。常规组在基础治疗基础上给予丁苯酞注射液治疗,观察组在常规组治疗基础上增加丹红注射液治疗。比较两组的治疗效果。结果 观察组的治疗总有效率显著高于常规组,差异具有统计学意义(P<0.05)。治疗后,观察组的神经元特异性烯醇化酶(NSE)、S100-β蛋白、8-羟基脱氧鸟苷(8-OHdG)及丙二醛(MDA)水平显著低于常规组,超氧化物歧化酶(SOD)、总抗氧化能力(T-AOC)及谷胱甘肽(GSH)水平显著高于常规组,差异具有统计学意义(P<0.05)。治疗后,观察组基底动脉的最大血流速度(Vmax)、最小血流速度(Vmin)及平均血流量(Qmean)显著高于常规组,外周阻力(RV)显著低于常规组,差异具有统计学意义(P<0.05)。两组的不良反应总发生率无显著差异(P>0.05)。结论 丹红注射液联合丁苯酞注射液治疗急性脑梗死患者可取得安全高效的临床效果,并改善氧化应激反应。

丁苯酞软胶囊联合替罗非班注射液治疗急性脑梗死的临床疗效

目的探讨丁苯酞软胶囊联合替罗非班注射液治疗急性脑梗死的临床疗效。方法选取2019年12月至2022年12月于开封市中心医院治疗的急性脑梗死患者60例作为研究对象,通过随机数字表法将研究对象分为联合组、单药组各30例。联合组在采用丁苯酞软胶囊联合替罗非班注射液治疗,单药组使用替罗非班注射液治疗,对比单药组、联合组血管内皮功能指标[内皮素-1(ET-1)、一氧化氮(NO)]、炎性指标[白细胞介素-6(IL-6)、肿瘤坏死因子α(TNF-α)、超敏C反应蛋白(hs-CRP)]、血液流变学(全血还原黏度、低切还原黏度、高切还原黏度)、神经功能评分(NIHSS)、临床疗效及不良反应发生率。结果治疗前两组ET-1、NO、IL-6、TNF-α、hs-CRP、全血还原黏度、低切还原黏度、高切还原黏度水平、NIHSS评分比较,差异无统计学意义(P>0.05);治疗后两组ET-1、TNF-α、IL-6、hs-CRP、全血还原黏度、低切还原黏度、高切还原黏度、NIHSS评分水平均低于治疗前,NO水平均高于治疗前,差异具有统计学意义(P<0.05);治疗后,联合组ET-1、TNF-α、IL-6、hs-CRP、全血还原黏度、低切还原黏度、高切还原黏度、NIHSS评分水平低于单药组,NO水平高于单药组,差异具有统计学意义(P<0.05);联合组临床疗效优于单药组,差异具有统计学意义(P<0.05);联合组不良反应发生率高于单药组,但差异无统计学意义(P>0.05)。结论丁苯酞软胶囊联合替罗非班注射液治疗可提高临床疗效,改善血管内皮功能及神经功能,有效恢复患者脑血流灌注,降低炎性反应促进恢复,效果理想。

通心络胶囊辅助治疗在脑梗死患者中的应用效果观察

目的:观察通心络胶囊辅助治疗在脑梗死患者中的应用效果。方法:选取2020年5月—2022年3月滨州市中心医院收治的脑梗死患者150例作为研究对象,采用随机数表法分为对照组与观察组,各75例。对照组接受常规治疗,观察组在对照组基础上接受通心络胶囊辅助治疗。比较两组治疗效果,纤维蛋白原、低密度脂蛋白胆固醇水平,活动能力,神经功能,大脑中动脉血流速度,不良反应发生情况。结果:观察组治疗总有效率高于对照组,差异有统计学意义(P=0.034);治疗后,两组纤维蛋白原、低密度脂蛋白胆固醇水平降低,观察组低于对照组,差异有统计学意义(P<0.001);治疗后,两组日常生活活动能力量表评分升高,美国国立卫生研究院卒中量表评分降低,大脑中动脉血流速度减慢,观察组优于对照组,差异有统计学意义(P<0.001);两组不良反应总发生率比较,差异无统计学意义(P>0.05)。结论:通心络胶囊辅助治疗在脑梗死患者中的应用效果显著,能改善患者凝血指标与血脂指标,提高活动能力,减轻神经功能损伤,改善血流动力学,且未增加不良反应发生风险。

依达拉奉右莰醇联合丹红治疗急性脑梗死患者效果及对血液流变学与miR-34c的影响

目的:研究依达拉奉右莰醇联合丹红注射液治疗急性脑梗死(ACI)患者的临床效果及对患者血液流变学与血清miR-34c水平的影响。方法:选取2021年8月—2023年2月104例入住在赣南医科大学第三附属医院的ACI患者作为研究对象,随机分为单一组和联合组。两组均进行常规治疗,在此基础上,单一组给予丹红注射液治疗,联合组给予依达拉奉右莰醇联合丹红注射液治疗,两组均治疗2周。观察患者治疗后临床疗效、治疗前后的神经功能、日常生活能力、血液流变学各指标和不良反应,抽取血样检测血清超氧化物歧化酶(SOD)、超敏C反应蛋白(hs-CRP)和miR-34c水平的变化。结果:治疗后联合组总有效率为90.38%,明显高于单一组的75.00%,两组差异有统计学意义(P<0.05)。治疗1、2周后,两组NIHSS评分、血液流变学各指标和hs-CRP水平均明显降低,且联合组均显著低于单一组(P<0.05);而Barthel指数评分、血清SOD和miR-34c水平均明显升高,且联合组均显著高于单一组(P<0.05)。两组的不良反应发生率比较,差异均无统计学意义(P>0.05)。结论:使用达拉奉右莰醇联合丹红注射液治疗ACI患者可以增强治疗效果和日常生活能力,改善患者的神经功能和血液流变学参数,并且能够提高血清miR-34c水平以抑制炎症反应。

急诊重组组织型纤溶酶原激活剂动脉溶栓联合丹红注射液治疗急性脑梗死的临床效果

目的观察急诊重组组织型纤溶酶原激活剂(recombinant tissue plasminogen activator,rt-PA)动脉溶栓联合丹红注射液对急性脑梗死(acute cerebral infarction,ACI)患者的临床效果。方法选取2020年5月至2021年5月禹城市中医院收治的90例ACI患者作为研究对象,随机分为观察组与对照组,每组45例。观察组行rt-PA动脉溶栓联合丹红注射液治疗,对照组仅行rt-PA动脉溶栓治疗。比较两组炎症因子水平、氧化应激指标、神经功能指标、血管内皮功能。结果治疗后,两组C反应蛋白(C-reactive protein,CRP)、白细胞介素-8(interleukin-8,IL-8)、白细胞介素-6(interleukin-6,IL-6)水平均低于治疗前,且观察组低于对照组,差异有统计学意义(P<0.05)。治疗后,两组超氧化物歧化酶(superoxide dismutase,SOD)水平均高于治疗前,丙二醛(malondialdehyde,MDA)水平均低于治疗前,且观察组SOD水平高于对照组,MDA水平低于对照组,差异有统计学意义(P<0.05)。治疗后,两组脑源性神经营养因子(brain derived neurotrophic factor,BDNF)水平均高于治疗前,神经元特异性烯醇化酶(neuron specific enolase,NSE)水平低于治疗前,且观察组BDNF水平高于对照组,NSE水平低于对照组,差异有统计学意义(P<0.05)。治疗后,两组血管内皮生长因子(vascular endothelial growth factor,VEGF)、一氧化氮(nitric oxide,NO)水平均高于治疗前,内皮素-1(endothelin-1,ET-1)水平均低于治疗前,且观察组VEGF、NO水平高于对照组,ET-1水平低于对照组,差异有统计学意义(P<0.05)。结论rt-PA动脉溶栓联合丹红注射液治疗ACI患者能减轻氧化应激反应,降低炎症因子水平,改善神经功能与血管内皮功能,值得临床推广应用。

丹红注射液治疗急性脑梗死临床观察

目的探讨丹红注射液治疗急性脑梗死的临床效果。方法选取2020年12月—2022年12月在宁河区大北涧沽镇卫生院接受治疗的100例急性脑梗死患者,随机分为常规治疗组和干预组,每组50例。常规治疗组给予奥扎格雷、阿司匹林抗凝治疗,干预组在常规治疗组基础上使用丹红注射液。记录2组患者的神经功能缺损以及血流变检查改变情况。结果干预组总有效率明显高于常规治疗组,P<0.05;干预组的血流变学各项检查优于常规治疗组,P<0.05。结论丹红注射液治疗急性脑梗死能够有效提高患者治愈率,改善神经功能,提高生活质量。

丹红注射液联合依达拉奉治疗急性脑梗死有效性及安全性系统评价

目的评价丹红注射液联合依达拉奉治疗急性脑梗死的疗效和安全性。方法通过检索中国生物医学文献数据库、中国期刊全文数据库、维普期刊数据库、万方期刊数据库、MEDLINE数据库从建库至2014年11月的中英文文献,选择符合纳入及排除标准的随机对照试验,对纳入文献进行质量评价,采用Rev Man5.2版软件进行Meta分析。结果共纳入23个研究,2 001例患者。丹红注射液联合依达拉奉注射液在疗效方面对比单用丹红注射液、依达拉奉注射液、丹参注射液及常规治疗有优势,疗效合并效应量[RR=1.23,95%CI(1.17,1.29),P<0.000 01];在神经功能缺损改善方面优于丹红注射液对照组,合并效应量[MD=-3.09,95%CI(-3.68,-2.50),P<0.000 01];在日常生活能力改善方面比丹红注射液对照组及依达拉奉对照组有效,合并效应量[MD=15.15,95%CI(12.69,17.62),P<0.000 01];而在安全性方面与对照组无差异,合并效应量[RR=1.88,95%CI(0.76,4.63),P=0.17]。结论丹红注射液联合依达拉奉注射液治疗急性脑梗死疗效较单用一种注射剂及常规治疗显著,能减轻近期致残率,且较安全,但仍需后续大样本、高质量文献关注致死率及远期致残率的研究。

丁苯酞胶囊联合血栓通注射液治疗急性脑梗死疗效和安全性的Meta分析

目的:系统评价丁苯酞胶囊联合血栓通注射液治疗急性脑梗死的疗效和安全性。方法:计算机检索Medline、Embase、the Cochrane Library、SCI、维普数据库、中国期刊全文数据库、万方数据库、中国生物医学文献数据库,数据库检索时限均从建库起截止2016年5月,根据Cochrane系统评价方法对纳入的随机对照试验进行方法学质量评价,并用Rev Man 5.2软件进行Meta分析。结果:共纳入7个随机对照试验,累计640例患者,Meta分析显示:在常规治疗的基础上,加用丁苯酞胶囊联合血栓通注射液治疗急性脑梗死的有效率高于加用血栓通注射液(RR=1.33,95%CI:1.16~1.52,P<0.000 1)、高于加用丁苯酞胶囊(RR=1.45,95%CI:1.15~1.83,P=0.002)、高于加用安慰剂(RR=1.31,95%CI:1.08~1.57,P=0.005);加用丁苯酞胶囊联合血栓通注射液治疗后患者的NHISS评分高于加用血栓通注射液(MD=4.63,95%CI:3.38~5.87,P<0.000 01)、高于加用安慰剂(MD=6.85,95%CI:4.90~8.80,P<0.000 01);不良反应分析显示,只有2项研究描述了不良反应发生率,差异无统计学意义。结论:丁苯酞胶囊联合血栓通注射液疗效优于对照组,但纳入研究质量较低,该结论还需高质量、大样本研究进一步验证。

脑心通胶囊联合丹红注射液治疗急性脑梗死的临床疗效及其机制探讨

目的观察脑心通胶囊联合丹红注射液治疗急性脑梗死的临床疗效,探讨其作用机制。方法选取2013年10月~2014年12月在武汉市中心医院神经内科住院的急性脑梗死患者90例,随机分为3组：对照组单纯应用抗血小板聚集、降脂、护脑及对症等常规治疗;治疗组在常规治疗同时给予脑心通胶囊治疗;联合用药组在常规治疗基础上加用脑心通胶囊和丹红注射液治疗。观察治疗前后三组患者的临床疗效、血液流变学、血脂代谢指标、炎症因子的变化。结果治疗组治疗前后神经功能缺损评分明显改善,且优于对照组（均P〈0.05）,联合用药组改善更明显（均P〈0.05）,治疗组和联合用药组总有效率均高于对照组（均P〈0.05）,联合用药组与治疗组总有效率差异无统计学意义（P〉0.05）,治疗组对降低脑梗死患者纤维蛋白原、血浆粘度、肿瘤坏死因子α（TNF-α）及白介素1β（IL-1β）作用明显强于对照组（均P〈0.05）;联合用药组降低纤维蛋白原、血浆粘度、TNF-α及IL-1β作用较治疗组更强（均P〈0.05）。血脂代谢方面,联合用药组与治疗组降总胆固醇及三酰甘油的作用相当,两者均高于对照组（均P〈0.05）。结论脑心通胶囊对急性脑梗死患者有较好的疗效,联用丹红注射液的疗效更佳,其可能作用机制为脑心通联合丹红注射液能降低患者血液纤维蛋白原、血浆粘度,降低TNF-α、IL-1β炎症因子的水平。

通心络胶囊治疗脑梗塞临床观察

目的 :观察通心络胶囊对脑梗塞的临床疗效。方法 :选择 16 0例脑梗塞住院患者 ,随机分为通心络组和丹参组 ,观察治疗前后临床神经功能缺损症状及实验室指标 (血脂、血液流变学、血小板聚集功能 )。结果 :治疗组总有效率为 89.77% ,对照组为 72 .2 2 % ,治疗组明显高于对照组 (P <0 .0 5 )。治疗组治疗后血脂、血液流变学、血小板聚集功能等各项实验室指标明显改善 ,其改善程度明显优于对照组。结论 :通心络具有调节血脂代谢、降低血液粘度、改善血液流变学、降低血小板聚集功能等作用、能有效改善脑部血液循环、减少迟发性神经元损害 ,改善脑梗塞病人的神经功能缺损症状。通心络胶囊为治疗和预防脑梗塞的有效药物。

丹红注射液辅助治疗对急性脑梗死患者神经损伤、血小板活化标志物的影响

目的:探讨丹红注射液辅助治疗对急性脑梗死患者神经损伤、血小板活化标志物的影响。方法:选择在本院接受治疗的急性脑梗死患者102例,回顾治疗方案并分为接受常规治疗的常规组54例、接受丹红注射液辅助治疗的丹红注射液组48例。对比两组患者治疗前、治疗3d后、治疗7d后血清神经损伤指标及外周血血小板活化标志物含量的差异。结果:治疗前,两组血清中神经损伤指标及外周血血小板活化标志物含量的差异无统计学意义。治疗3d后、治疗7d后,丹红注射液组患者血清中copeptin、H-FABP、NSE的含量低于常规组,BDNF、bFGF的含量高于常规组;外周血中CD62p、CD42b、PAC-1、PMA的含量低于常规组。结论:急性脑梗死患者在常规治疗基础上加入丹红注射液辅助治疗,可有效减轻患者神经损伤程度并抑制血小板激活。

通心络胶囊配合治疗急性脑梗死的临床研究

目的 :观察通心络胶囊对急性脑梗死的治疗效果以及对患者凝血 -纤溶指标的影响 ,以综合分析其作用机理。方法 :将 6 4例急性脑梗死患者随机分为两组 ,通心络胶囊加常规药物治疗组 (治疗组 ) 33例 ,对照组 31例。观察两组患者治疗后有效率 ,治疗前后神经功能缺损评分、组织型纤溶酶原激活剂 (tPA)、纤溶酶原激活物抑制剂 (PAI)、抗凝血酶 Ⅲ (AT Ⅲ )、血栓素B2 (TXB2 )及 6 -酮 -前列腺素F1α(6 keto PGF1α)的变化。结果 :治疗组总有效率为 84 8%、平均减少积分为 (9 33± 4 4 7)分 ,明显优于对照组的 71 0 %、(8 5 0± 4 6 0 )分 (P <0 0 5 ) ;在升高血浆AT Ⅲ含量、降低TXB2 、升高TXB2 / 6 keto PGF1α比值方面与对照组比较 ,差异有显著性 (P <0 0 5 )。结论 :通心络胶囊作为急性脑梗死联合用药 ,可明显提高临床疗效 ;其作用机制可能与其抗凝及抑制血小板活化有关。